Litcius/Paper detail

Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension

Michele D’Alto, Roberto Badagliacca, Francesco Lo Giudice, Paola Argiento, Gavino Casu, Marco Corda, Michele Correale, Stefano Ghio, Alessandra Greco, Mariangela Lattanzio, Valentina Mercurio, Giuseppe Paciocco, Silvia Papa, Renato Prediletto, Emanuele Romeo, Maria Giovanna Russo, Alessandro Tayar, Patrizio Vitulo, Carmine Dario Vizza, Paolo Golino, Robert Naeije

2020The Journal of Heart and Lung Transplantation41 citationsDOI

Topics & Concepts

AmbrisentanTadalafilMedicineInternal medicinePulmonary arteryPulmonary hypertensionCardiologyHemodynamicsBlood pressureVascular resistanceErectile dysfunctionBosentanEndothelin receptorReceptorPulmonary Hypertension Research and TreatmentsPhosphodiesterase function and regulationInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension | Litcius